| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Zynerba Pharmaceuticals, Inc. | Vice President, Corporate Controller and Interim Chief Financial Officer | Common Stock | 0 | $1.33 | 10 Oct 2023 | Direct | |
| Zynerba Pharmaceuticals, Inc. | Vice President, Corporate Controller and Interim Chief Financial Officer | Stock Option (Right to Buy) | 0 | 10 Oct 2023 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| /report/000114036123047746-jones-kenneth-t-2023-10-10 | Zynerba Pharmaceuticals, Inc. | 10 Oct 2023 | 4 | $0 | 4 | Vice President, Corporate Controller and Interim Chief Financial Officer | 11 Oct 2023, 10:17 |
| /report/000106299323018019-jones-kenneth-t-2023-09-12 | Zynerba Pharmaceuticals, Inc. | 12 Sep 2023 | 2 | -$3,321 | 4 | Vice President, Corporate Controller and Interim Chief Financial Officer | 14 Sep 2023, 16:13 |
| /report/000106299323016508-jones-kenneth-t-2023-08-08 | Zynerba Pharmaceuticals, Inc. | 08 Aug 2023 | 0 | $0 | 3 | Officer | 15 Aug 2023, 16:05 |